Приказ основних података о документу

dc.creatorCassetta, Luca
dc.creatorBruderek, Kirsten
dc.creatorSkrzeczynska-Moncznik, Joanna
dc.creatorOsiecka, Oktawia
dc.creatorHu, Xiaoying
dc.creatorRundgren, Ida Marie
dc.creatorLin, Ang
dc.creatorSantegoets, Kim
dc.creatorHorzum, Utku
dc.creatorGodinho-Santos, Ana
dc.creatorZelinskyy, Gennadiy
dc.creatorGarcia-Tellez, Thalia
dc.creatorBjelica, Sunčica
dc.creatorTaciak, Bartlomiej
dc.creatorKittang, Astrid Olsnes
dc.creatorHoeing, Benedikt
dc.creatorLang, Stephan
dc.creatorDixon, Michael
dc.creatorMueller, Verena
dc.creatorUtikal, Jochen Sven
dc.creatorKarakoc, Derya
dc.creatorYilmaz, Kerim Bora
dc.creatorGorka, Emilia
dc.creatorBodnar, Lubomir
dc.creatorAnastasiou, Olympia Evdoxia
dc.creatorBourgeois, Christine
dc.creatorBadura, Robert
dc.creatorKapinska-Mrowiecka, Monika
dc.creatorGotić, Mirjana
dc.creatorter Laan, Mark
dc.creatorKers-Rebel, Esther
dc.creatorKrol, Magdalena
dc.creatorSantibanez, Juan F.
dc.creatorMueller-Trutwin, Michaela
dc.creatorDittmer, Ulf
dc.creatorde Sousa, Ana Espada
dc.creatorEsendagli, Gunes
dc.creatorAdema, Gosse
dc.creatorLore, Karin
dc.creatorErsvaer, Elisabeth
dc.creatorUmansky, Viktor
dc.creatorPollard, Jeffrey W.
dc.creatorCichy, Joanna
dc.creatorBrandau, Sven
dc.date.accessioned2021-04-20T13:06:12Z
dc.date.available2021-04-20T13:06:12Z
dc.date.issued2020
dc.identifier.issn2051-1426
dc.identifier.urihttp://rimi.imi.bg.ac.rs/handle/123456789/994
dc.description.abstractBackground Myeloid-derived suppressor cells (MDSC) are a functional myeloid cell subset that includes myeloid cells with immune suppressive properties. The presence of MDSC has been reported in the peripheral blood of patients with several malignant and non-malignant diseases. So far, direct comparison of MDSC across different diseases and Centers is hindered by technical pitfalls and a lack of standardized methodology. To overcome this issue, we formed a network through the COST Action Mye-EUNITER () with the goal to standardize and facilitate the comparative analysis of human circulating MDSC in cancer, inflammation and infection. In this manuscript, we present the results of the multicenter study Mye-EUNITER MDSC Monitoring Initiative, that involved 13 laboratories and compared circulating MDSC subsets across multiple diseases, using a common protocol for the isolation, identification and characterization of these cells. Methods We developed, tested, executed and optimized a standard operating procedure for the isolation and immunophenotyping of MDSC using blood from healthy donors. We applied this procedure to the blood of almost 400 patients and controls with different solid tumors and non-malignant diseases. The latter included viral infections such as HIV and hepatitis B virus, but also psoriasis and cardiovascular disorders. Results We observed that the frequency of MDSC in healthy donors varied substantially between centers and was influenced by technical aspects such as the anticoagulant and separation method used. Expansion of polymorphonuclear (PMN)-MDSC exceeded the expansion of monocytic MDSC (M-MDSC) in five out of six solid tumors. PMN-MDSC expansion was more pronounced in cancer compared with infection and inflammation. Programmed death-ligand 1 was primarily expressed in M-MDSC and e-MDSC and was not upregulated as a consequence of disease. LOX-1 expression was confined to PMN-MDSC. Conclusions This study provides improved technical protocols and workflows for the multi-center analysis of circulating human MDSC subsets. Application of these workflows revealed a predominant expansion of PMN-MDSC in solid tumors that exceeds expansion in chronic infection and inflammation.en
dc.publisherBMJ Publishing Group, London
dc.relationCOST action [BM1404 - Mye-EUNITER]
dc.relationGrant from the Deutsche Forschungsgemeinschaft to SB (DFG, BR 2278/6–1)
dc.relationWellcome Trust (101067/Z/13/Z)
dc.relationMRC Centre\grant MR/N022556/1 to JWP
dc.relationSTOPbraintumors Foundation
dc.relationCOST action
dc.relationGrants from the Dutch Cancer Society awarded to GA and CBüll (KUN2015-7604) and GA, KS and P Wesseling (KWF11266)
dc.relationGrant from German Research Council RTG2099/2 (JSU, VU)
dc.relationinfo:eu-repo/grantAgreement/MESTD/inst-2020/200015/RS//
dc.relationThe Scientific and Technological Research Council of Turkey, (TÜBİTAK; project no. 115S636)
dc.relationCOST action [BM1404 - Mye-EUNITER]
dc.relationEuropean Research Council (ERC) under the European Union’s Horizon 2020 research and innovation programmeprogram (Grant agreement No. 715048)
dc.relationPasteur Paris University International PhD program
dc.relationInstitut Carnot Microbes et Sante
dc.relationSidaction
dc.relationFEDER through Programa Operacional Regional de Lisboa, do PORTUGAL 2020 [PTDC/MED--IMU/30474/2017, LISBOA-01-0145--FEDER-030474]
dc.relationFundacao para a Ciencia e a Tecnologia, Portugal
dc.relationGilead Genesis
dc.relationPolish National Science Center [UMO-2011/02/A/NZ5/00337, UMO-2017/25/B/NZ6/01003]
dc.relationSwedish Research Council (2019–01036)
dc.relationFaculty of Engineering and Natural Sciences, Western Norway University of Applied Sciences, Norway
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by-nc/4.0/
dc.sourceJournal for Immunotherapy of Cancer
dc.subjectbiomarkersen
dc.subjecttumoren
dc.subjectimmunityen
dc.subjectcellularen
dc.subjectimmunoassayen
dc.subjectmyeloid-derived suppressor cellsen
dc.subjecthead and neck neoplasmsen
dc.titleDifferential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammationen
dc.typearticle
dc.rights.licenseBY-NC
dc.citation.issue2
dc.citation.other8(2): -
dc.citation.spagee001223
dc.citation.volume8
dc.identifier.doi10.1136/jitc-2020-001223
dc.identifier.fulltexthttp://rimi.imi.bg.ac.rs/bitstream/id/792/991.pdf
dc.identifier.pmid32907925
dc.identifier.scopus2-s2.0-85090819648
dc.identifier.wos000576255300006
dc.type.versionpublishedVersion


Документи

Thumbnail

Овај документ се појављује у следећим колекцијама

Приказ основних података о документу